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Abstract:  Like many animal viruses, those of the Rhabdoviridae family, are able to 
antagonize the type I interferon response and cause disease in mammalian hosts. Though 
these negative-stranded RNA viruses are very simple and code for as few as five proteins, 
they have been seen to completely abrogate the type I interferon response early in 
infection. In this review, we will discuss the viral organization and type I interferon 
evasion of rhabdoviruses, focusing on vesicular stomatitis virus (VSV) and rabies virus 
(RABV). Despite their structural similarities, VSV and RABV have completely different 
mechanisms by which they avert the host immune response. VSV relies on the matrix 
protein to interfere with host gene transcription and nuclear export of anti-viral mRNAs. 
Alternatively, RABV uses its phosphoprotein to interfere with IRF-3 phosphorylation and 
STAT1 signaling. Understanding the virus-cell interactions and viral proteins necessary to 
evade the immune response is important in developing effective vaccines and therapeutics 
for this viral family.  
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1. Introduction 
The Rhabdoviridae family is comprised of more than 175 different currently classified viruses, 
which are able to infect vertebrates, invertebrates and plants. Common features shared by all 
rhabdoviruses are an elongated bullet-like shape and an enveloped virion that contains a single-
stranded nonsegmented RNA genome. In addition, rhabdoviral genomes encode a basic set of five 
structural proteins: a nucleoprotein (N), a phosphoprotein (P), a matrix protein (M), a single trans-
membrane glycoprotein (G), and an RNA-dependent RNA polymerase (L). Of note, plant as well as 
some animal rhabdoviruses can encode up to four additional nonstructural proteins  [1]. In principle, 
these nonstructural proteins could be involved in suppression or evasion of host antiviral responses. 
However, to date the only known mechanisms involve structural proteins that serve dual functions in 
both virus replication and suppression of host responses.  
Although the viruses classified in the Rhabdoviridae family have many similarities, there are also 
important differences in the way different members interact with the host defense mechanisms. This is 
presumably due to the different defense mechanisms within their hosts. Whereas in plant and insect 
cells micro RNA (miRNA) probably play a major role in host defense mechanism against rhabdoviral 
infections  [2,3], in higher vertebrates the production of type I interferon (IFN) and initiation of the 
innate immune response is critical. Most viral pathogens of higher vertebrates are sensitive to IFN-
induced antiviral proteins (see other articles in this issue), and thus, have adapted individual 
mechanisms to avert the innate immune response. This review will focus on type I interferon induction 
and evasion by two well-studied animal pathogens rabies virus (RABV) and vesicular stomatitis virus 
(VSV). These viruses are representative of two major Rhabdovirus genera, Lyssavirus  and 
Vesiculovirus, respectively. These viruses are quite similar in their mechanisms of replication, but 
differ markedly in their host range, pathogenesis, and mechanisms of immune evasion. 
More than twenty years ago type I IFN production in response to RABV infection, especially at the 
site of infection, was described  [4]. It has also been reported that the high levels of IFN in the serum 
early following infection with RABV contributes to viral resistance  [5]. Furthermore, mice injected 
with anti-mouse IFN- antibody prior to infection with RABV were more sensitive to the virus than 
mice injected with a control antibody  [4]. Likewise, when the IFN- gene was cloned into the RABV 
backbone, it was seen that the recombinant virus had greatly reduced pathogenicity and viral 
replication in mice, however the immunogenicity of RABV was not decreased  [6].  
Similar observations for the importance of IFN- induction have been made following VSV 
infection. Type I IFN has been shown to be critical for resistance of mice to infection with VSV. For 
example, mice deficient in molecules required for IFN-mediated signaling are more sensitive to VSV 
infection than wildtype mice  [7,8]. Interestingly, wild-type VSV infections do not induce type I IFN 
production in the central nervous system of mice, however type I IFN is rapidly induced in the 
periphery of these animals  [9], which serves to protect most tissues from viral pathogenicity. Taken 
together, these findings imply that type I IFN plays a major role in the viral lifecycle of RABV and 
VSV. Furthermore, it indicates that both viruses have developed mechanisms to interfere with the 
innate host response in order to establish productive infections in their hosts. Viruses 2009, 1                                       
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2. Genomic Organization and Viral Lifecycle of RABV and VSV  
In order to better understand the host innate immune response to RABV and VSV infection, we will 
first briefly describe the genomic organization and the viral lifecycle. As listed above rhabdoviruses 
encode a “basic set” of five proteins, which are encoded on a genome that has a gene order of 3’ N-P-
M-G-L 5’. In addition, all rhabdoviruses contain a noncoding 3’-leader RNA and a non-transcribed 
trailer sequence at the 5’ end. The rhabdoviral genes are flanked by intergenic sequences, which are in 
part conserved between all members of the family  [10,11]. Following transcription, the viral proteins 
are translated from monocistronic mRNAs.  
The N protein of rhabdoviruses encapsulates the RNA genome and antigenome into a tight, RNase-
resistant core  [12]. Only the encapsidated RNA, termed the ribonucleoprotein (RNP), is a functional 
template for transcription and replication. It is also thought that the level of N protein in the cells 
regulates the switch from transcription to replication by interactions with the leader RNA (leRNA) 
sequence  [13]. It is speculated that if enough N protein is available within the cell, encapsidation of 
the leRNA sequence results in the synthesis of a full-length antigenome rather the production of 
individual viral mRNA, therefore switching transcription to replication  [13].  
The P protein serves as the non-catalytic subunit to the viral transcriptase complex. Once P is 
phosphorylated it was proposed to form trimers that are able to bind L and N  [14]. However, more 
recently structural analysis revealed that P is dimmer or tetramer  [15-17]. Another function of P is to 
serve as a chaperone for N and prevent it from aggregation  [18,19]. Additionally, RABV P is able to 
antagonize interferon signaling, as discussed in subsequent sections of this review.  
The M protein is able to interact both with the nucleocapsid and with the cellular plasma 
membrane  [20]. Thus, the primary function of a rhabdoviral M protein is to bridge the viral membrane 
containing envelope and the nucleocapsid core during viral assembly and budding. The balance 
between transcription and replication is thought to be dependent on the M protein in addition to the 
quantity of N in the infected cell  [21]. A high concentration of VSV M inhibits RNA synthesis in 
vitro  [22]. It has been proposed that the association of RNP with VSV M results in the condensation 
of the RNP molecule, which renders it non-functional for transcription and replication. In addition, M 
has been seen to have secondary functions following VSV infection that might have been evolved 
later. Namely, VSV M has the ability to inhibit host defense mechanisms like type I interferon 
signaling, which will be discussed later in this review. 
The fourth gene encodes the G protein, which is the only trans-membrane glycoprotein in this 
family of viruses. The G proteins trimerize in the ER  [23] and the association is further stabilized by 
lateral interactions among trimers on the virion’s surface  [24]. At lower pH values the G protein 
undergoes a conformational change, which exposes hydrophobic residues allowing for fusion with 
target membranes   [25,26]. It is interesting to note that for both VSV G and RABV G, the pH 
dependent conformational changes required for fusion are reversible  [27,28].  
The catalytic subunit of the rhabdoviral polymerase complex is the large (L) protein. In addition to 
transcription, this large protein is capable of capping and methylating the 5’ end of the mRNA ( [29] 
and  [30], respectively) and polyadenylating the 3’ end  [31].  
As with many viruses, the lifecycle of Rhabdoviridae can be divided into three distinct phases: 
uncoating, transcription/ replication, and viral assembly. The first phase initiates when a viral particle Viruses 2009, 1                                       
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binds to the surface of a host cell and enters by endocytosis. Attachment to the host cell requires the G 
protein. However, it is less clear which cellular molecule(s) interacts with G to mediate viral entry. Of 
note, the nicotinic acetylcholine receptor  [32], neuronal cell adhesion molecule  [33] and low-affinity 
nerve-growth factor receptor (P75NTR) [34] has been suggested as receptors for RABV. On the other 
hand, VSV G protein appears to interact with negatively charged lipids on the cell surface through a 
combination of electrostatic and hydrophobic interactions   [35-37]. Following receptor binding, 
rhabdoviruses are endocytosed. Once in an endosome, the viral membrane fuses with the endosomal 
membrane to release the genome into the cytosol. Fusion of the virus with host membranes requires a 
change to a lower pH within the vesicle. Consequently, membrane fusion and the release of the capsid 
into the cytosol can be inhibited by both ammonium chloride and chloroquine  [38,39].  
In the second phase, virion components are produced. Direct translation of the rhabdoviral genome 
cannot occur because its RNA is negative sense, and furthermore, direct translation is prevented by the 
encapsidation of the genome by N  [40-43]. Thus, after release into the host cell cytosol the viral 
polymerase complex contained within the capsid is responsible for the RNA synthesis. The most 
widely accepted model for transcription of rhabdoviruses is the so-called stop/start model, where the 
polymerase stops at a signal sequence and restarts transcription at the transcription start signal 
sequence  [44]. Reinitiation of transcription by the polymerase complex for the following gene does 
not always occur; therefore, attenuation of transcription occurs in a 3’ to 5’ direction  [45]. Probably 
caused by the concentration of N protein, the viral polymerase switches to replication and transcribes a 
full-length anti-genomic RNA, which is also encapsidated into the N protein and serves a template for 
the replication of new genomic RNAs . 
The last phase of the life cycle is the assembly of the viral components, budding and finally release 
of the virions. For this process, the RNP-complex must be engulfed in the host cell membrane. It is as 
of yet unknown how the capsid is transported to the cellular membrane. Budding seems to be at least 
partially dependent on G, as in the absence of RABV-G RABV is released 30-fold less efficiently  [46] 
and similar finding have been made for VSV  [47]. More dramatically, in the absence of RABV M 
viral titers were reduced as much as 500,000 fold, but this did not greatly affect viral protein 
expression  [48]. Likewise, VSV M plays a role in seizing the endosomal-membrane fusion machinery 
to facilitate viral budding. This occurs via the PPPY motif near the N-terminus of VSV M, which 
allows for interaction with the cellular enzyme Nedd4  [49]. 
3. Viral Induced Expression of Type I Interferon 
The hallmark response to viral infection is the induction of type I interferon (IFN). This class of 
cytokines is comprised of several IFN- genes, a single IFN- gene, and the more recently added, and 
less well-defined, genes such as IFN-, -, -, -, and – [50]. All nucleated cells have the ability to 
both produce type I IFN and also to respond to it via a common heterodimeric receptor  [51]. Type I 
IFNs have been seen to induce an anti-viral state in cells, which makes them resistant to subsequent 
viral infection  [52]. In addition, this group of cytokines helps to initiate the adaptive immune response 
following infection  [6,53,54].  
A variety of viral moieties can trigger activation of the IFN- signaling cascade by numerous 
pathogen pattern recognition receptors (PRRs). In each case however, the signaling culminates in the Viruses 2009, 1                                       
 
 
836
binding of cytoplasmic transcription factors, namely IFN regulatory factor-3 (IRF-3) and nuclear 
factor kappa B (NF-B), to the IFN- promoter. Following signaling initiation, the C-terminus of IRF-
3 is phosphorylated and the proteins dimerize. This dimerization reveals a nuclear-localization signal 
(NLS) on IRF-3, which allows for transport into the nucleus  [55]. Alternatively, cytoplasmic NF-B 
can translocate to the nucleus following signal induced ubiquitination and proteasomal degradation of 
inhibitor of NF-B (IB) (for review see  [56]). Optimal binding and induction of IFN- requires the 
additional binding of c-jun/ATF-2 to the IFN- promoter. When all three transcription factors 
complexes assemble onto the promoter it is referred to as the enhanceasome. The enhanceasome aids 
in the recruitment of CREB-binding protein (CBP)/p300, which promotes the assembly of the 
transcriptional machinery and RNA polymerase II  [57]. Each transcription factor can bind to the IFN-
 promoter individually, however with limited affinity. It is generally accepted that the binding of IRF-
3 is indispensable for induction, while the binding of NF-B and c-jun/ATF-2 is not required  [58]. 
Similarly, the transcription of most interferon- genes requires activation of IRF-7, whose expression 
is induced in response to interferon- in many cell types  [59]. 
The upstream signaling mechanisms leading to type I interferon production vary markedly among 
different cell types depending on the expression of various pattern recognition receptors. The receptors 
that have been demonstrated to be important for the response to rhabdoviruses include Toll-like 
receptors (TLR), which are expressed either on the cell surface or in the endosomal compartment, and 
RIG-I-like receptors, which are expressed in the cytoplasm. 
3.1. Toll-like Receptor Signaling 
Signaling through many Toll-like receptors can induce IFN-. One such receptor is TLR-3, which 
is located in the endosome and binds double stranded RNA molecules  [60]. Following ligand binding, 
TLR-3 dimerizes and is phosphorylated at a tyrosine residue. It then recruits the adaptor molecule 
TIR-domain containing adaptor inducing IFN- (TRIF)  [61] which leads to the activation of both IRF-
3 and NF-B by divergent signaling cascades  [62].  
Negative stranded RNA viruses do not produce double stranded RNA as part of their normal 
replication cycle, since the negative RNA strand is always encapsidated. However, it is likely that 
abnormal replication products resulting from errors by viral RNA-dependent RNA polymerases give 
rise to some level of double stranded RNA in virus-infected cells  [63]. Using mice deficient in TLR-3, 
it was determined that this receptor is dispensable in clearing VSV, as mice remained resistant to 
infection despite the loss of TLR-3 signaling  [64]. On the other hand, TLR-3 signaling following a 
RABV infection may play a role in the induction of IFN-by infected neurons. Following infection 
of human postmitotic neurons with RABV, Prehaud et al. saw an increased production of IFN- and 
TLR-3 mRNAs. Treatment of neurons with poly(I:C), a TLR-3 agonist, generated similar cytokine 
profile to that which was seen following RABV infection  [65]. Furthermore, the expression of TLR-3 
on cerebellar cortex tissues of individuals that had died of rabies, but not on an individual that died of 
cardiac arrest, verify the viral induced expression of TLR-3 in human brains in vivo  [66]. Although 
this data did not definitively prove a role for TLR-3 in the innate immune response to RABV, it does 
provide evidence that TLR-3 signaling could be involved. Interestingly however, TLR3-/- mice have a 
reduced susceptibility to a pathogenic RABV stain, CVS-11  [67]. This increase in survival may be Viruses 2009, 1                                       
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unrelated to the IFN-response and rather due to the requirement of TLR-3 in forming viral Negri 
Bodies, which are suggested to be required for viral replication  [67,68]. 
Unlike TLR-3, which has relatively wide tissue distribution, another TLR capable of inducing IFN-
, TLR-7, has a much more restricted expression profile. TLR-7 is expressed primarily in different 
subclasses of dendritic cells, such as plasmacytoid dendritic cells (pDCs), a cell type that can produce 
the majority of the circulating IFN following a viral infection (for review see  [69]). The ligands for 
TLR-7 are immunomodulatory compounds (ie-imiquimod)   [70] or single-stranded RNA 
molecules   [71]. Upon ligand binding, TLR-7 recruits the adaptor protein myeloid differentiation 
factor 88 (MyD88), which then mediates IFN-/ production. MyD88 can complex with several 
proteins, namely TRAF-6 and IRAK-1, and initiate the direct binding of IRF-7  [72-74]. Following 
recruitment into the complex, IRF-7 is phosphorylated by IRAK-1 and translocates to the nucleus 
where it binds to the promoters for type I IFNs..  
Although the role for TLR-7 signaling following a RABV infection has yet to be determined, it 
appears that TLR-7 dependant signaling is important in the type I IFN response to VSV. Infection of 
wild type pDCs with VSV induced the production of both IFN-a and IL-12 p40. However, infection of 
pDCs from TLR7-/- or MyD88-/- mice resulted in no cytokine production  [75]. Thus, indicating that 
single-stranded RNA derived from VSV is able to trigger TLR-7 signaling. The response of dendritic 
cells to VSV seems to be restricted to TLR7
+ DC, as no IFN- production is seen following infection 
of myeloid DCs that do not express TLR-7  [76,77]. Interestingly however, when myeloid DCs are 
infected with an M-mutant VSV they are able to induce a type I IFN response, albeit independent of 
MyD88 signaling  [77].  
VSV replication is required to activate TLR-7 signaling in plasmacytoid DCs  [78,79]. However, as 
discussed above, VSV replication occurs in the cytoplasm, and thus replication intermediates, such as 
ssRNA, are spacially removed from endosomal TLR-7. It was hypothesized that autophagy may play a 
critical role in bringing ligand and receptor into the same subcellular compartment following VSV 
infection. To address this possibility, Lee et al. treated pDCs with inhibitors of autophagy, either 
Wortmannin or 3-MA, prior to infection. It was seen that the inhibitors had no effect on VSV infection 
rates, but that they did inhibit IFN- production in a dose-dependent manner  [78]. Thus, indicating a 
critical role for autophagy in initiating TLR-7 signaling in VSV infected cells.  
TLR-4 is also able to induce both IRF-3 and NF-B signaling in response to extracellular signals. 
Although TLR-4 is generally associated with its ability to bind bacterial products, namely 
lipopolysaccharide, it has been seen that VSV G can trigger IFN- production via TLR-4 
signaling  [80]. Furthermore, this type I IFN response may be important to disease outcome because 
while more than 50% of the TLR-4-/- mice succumbed intravenous VSV challenge, 100% of wild type 
mice survived  [80].  
3.2. RIG-I-like Receptor Signaling 
In addition to TLRs, cells can also induce type I IFN via a cytoplasmic pattern recognition receptor 
family, the RIG-I-like receptors (RLR). Like TLR signaling, RLR signaling converges on NF-B and 
IRF-3 to induce a robust IFN- response. Two of these receptors, namely retinoic acid-inducible 
gene-I (RIG-I) and melanoma differentiation-associated gene-5 (Mda-5), have been reported to be Viruses 2009, 1                                       
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important in the recognition of RNA viruses  [81]. Signaling by RIG-I and Mda-5 is mediated through 
the mitochondria-bound protein interferon beta promoter stimulator-1 (IPS-1), which is also referred to 
as MAVS, Cardif, or VISA  [82-85]. Of note, IPS-1’s localization in the mitochondria is critical for 
activation of IRF-3 and NF-B  [84]. IPS-1, with the help of TRAF-3, facilitates the activation of two 
kinases, TANK-binding kinase-1 (TBK1) and IKKi (also known as IKKe), that go on to activate IRF-
3  [82,86].  
Whereas Mda-5 signaling has been seen to be important in the IFN- response to 
picornaviruses   [87], RIG-I signaling is critical in generating type I IFN following a rhabdovirus 
infection. Although the L protein of rhabdoviruses has a capping function   [29], the leader RNA 
remains unmodified  [88,89]. Thus, viral transcription generates some single-stranded RNA molecules 
bearing a 5’ triphosphate, which is one of the known ligands for RIG-I. Following infection with a 
recombinant RABV that expressed very little P, IFN- promoter activity was reported, however 
transfection of a dominant-negative mutant RIG-I molecule prior to infection abrogated the 
response   [90]. Thus indicating, that RIG-I was responsible for the IFN-response following 
infection. Interestingly, viral replication does not seem to be required for IFN induction as transfection 
of RNA isolated from RABV infected cells was sufficient to induce a response. On the other hand, the 
presence of 5’-triphosphate RNA was observed to be essential for eliciting a type I IFN response as 
dephosphorylated viral RNA induced no IFN- promoter activity  [90].  
RIG-I signaling has also been reported to be important for generating IFN-following infection 
with VSV. Following intranasal infection with VSV, RIG-I expression in microglia and astrocyte 
cultures is upregulated  [91]. It was also seen that unlike in wildtype cells, mRNA for IFN- and 
CXCL10 was not upregulated in mouse embryo fibroblasts (MEFs) from RIG-I-/- mice   [92]. 
Additionally following infection with VSV, RIG-I-/- MEFs had a 1.5-log increase in viral titers 
compared to wildtype cells   [92]. This phenotype was reproduced in vivo, as RIG-I-/- mice were 
significantly more susceptible to an intranasal infection with VSV than wildtype littermate 
controls  [87]. Furthermore, it was determined that RIG-I, but not Mda-5, was responsible for inducing 
the type I IFN response after VSV infection  [87]. 
4. Type I Interferon Induced Antiviral State Following Infection 
As mentioned above, the receptor for type I IFN is expressed on a wide range of cells. Additionally, 
IFN- can act in both an autocrine and paracrine manner to induce an anti-viral state in the cell. 
When IFN- binds to its heterodimeric receptor oligomerization and a subsequent conformational 
change occurs allowing members of the Janus kinase (JAK) family to phosporylate the IFNAR1 
subunit. The phosphorylated receptor subunit can then act as a docking site for members of the signal 
transducers and activators of transcription (STATs), which are in turn phosphorylated by JAKs  [50]. 
Once STAT-1 and STAT-2 are phosphorylated they dimerize and create a novel NLS, which allows 
for their transport into the nucleus. The STAT1/2 complex forms a heterotrimer with IRF-9 either in 
the nucleus or at the receptor, making what is referred to as the ISGF3 complex. The canonical 
activation of IFN-stimulated genes (ISGs) occurs by ISGF3 binding to the IFN-stimulated response 
element (ISRE) present in the promoter of most ISGs  [50]. Of note, all of the components that make 
up the ISGF3 are IFN-inducible.  Viruses 2009, 1                                       
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Following treatment with IFN-, the transcript frequency for numerous genes increases  [93]. 
Many of these gene products encode proteins or transcription factors involved in the aforementioned 
signaling cascades, thus acting as an amplification loop to increase the amount of type I IFN produced. 
Other genes encode for proteins with direct antiviral functions. Here we will only discuss the antiviral 
gene products that have been shown to play a role in a RABV or VSV infection, however that does not 
imply that those genes not discussed do not play a role in the innate response to these or other 
rhabdoviruses. 
One such anti-viral protein is the Mx family of GTPases, which are highly induced in response to 
type I IFN. The main viral target for these proteins is nucleocapsid-like structures and after binding 
they appear to sequester the viral proteins and interfere with proper localization  [94]. It was seen that 
expression of bovine Mx1 can reduce viral titers and decrease N protein levels in rabies infected 
VERO cells   [95]. Likewise, VSV replication is inhibited by a wide variety of Mx proteins in 
vitro   [96-98]. The human MxA protein was seen to inhibit both viral mRNA and protein levels 
following infection with VSV for 5 hours  [98]. Furthermore, transgenic mice that express high levels 
of bovine Mx1 are resistant to a lethal challenge of VSV  [99]. 
Another IFN-induced gene that affects both RABV and VSV is promyelocytic leukaemia (PML). 
PML is expressed in the nucleoplasm and nuclear bodies (NB) of the cell. Following IFN- 
treatment, enhanced PML protein expression is seen and the NB size markedly increases  [100,101]. 
The anti-viral properties of PML are still unclear, however it is known that expression is essential for 
type I IFN induced apoptosis  [102] and that PML has growth suppressing properties  [100]. Like Mx 
proteins, it was observed that overexpression of PMLIII induced resistance to VSV infection, by 
inhibiting mRNA and protein synthesis  [103]. Of note, complete inhibition by PML was only seen 
following infections at a low multiplicity of infection   [103]. Furthermore, following type I IFN 
treatment MEFs derived from PML-/- mice had similar resistance to VSV infection as seen in wildtype 
cells   [101]. The anti-viral role of PML following a RABV infection has not, as of yet, been 
experimentally proven. Rather, an anti-viral role is hypothesized due to RABV P protein’s ability to 
disrupt NB organization and increased rabies virus replication, as seen by higher protein level 
expression and 20 times more virus, in PML-/- MEFs  [104]. The details of RABV induced PML 
inhibition will be discussed in detail in the next section. 
Although the antiviral effects induced by Mx/ PML is similar for RABV and VSV, there are a 
number of antiviral proteins that have only been reported to play a role following VSV infection, 
namely PKR and ISG15. PKR and ISG15 have completely unique mechanisms to alter the host 
response to a viral infection. PKR is constitutively expressed in all tissues, however it is activated and 
upregulated by either dsRNA or type I IFN treatment. PKR phosphorylates eukaryotic translational 
initiation factor (eIF)-2, which results in the sequestering of eIF2-B. Thus, translation initiation is 
halted   [105]. Mice deficient in PKR are much more sensitive to intranasal VSV infections than 
wildtype mice  [106-108].  
Alternatively, ISG15 is an ubiquitin homologue that activates its substrates, rather than targeting 
them for degradation  [109]. ISG15 substrates include, among others, signaling components in the 
JAK/STAT and RIG-I pathways, MxA, and PKR  [110]. The requirement for ISG15 in the innate 
response to VSV is still unknown, due to conflicting results. Lu et al. noted that ISG15-/- MEFs are 
more permissive to VSV replication, however there was no notable differences in the knockout cells’ Viruses 2009, 1                                       
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sensitivity to the antiviral effect of IFN-  [109]. On the other hand, using a knockout mouse that 
was only deficient in ISG15 conjugation, not free ISG15, there was no difference in the susceptibility 
of cells to VSV in an IFN-protection assay  [111]. Of note, ISG15 is regulated by USP18, which 
catalyzes its hydrolysis to remove it from conjugated proteins  [112,113]. Interestingly, USP18-/- mice 
show an increased survival following intracerebral infection with VSV as compared to wildtype 
mice  [114].  
5. Rhabdoviruses IFN- Antagonism Mechanisms 
In order for an effective infection to occur, RABV and VSV must antagonize the interferon 
signaling cascade and block induction of antiviral molecules. However, RABV and VSV have 
completely different mechanisms by which they antagonize the immune response. RABV specifically 
targets signaling molecules in order to block IFN induction and subsequent responses. On the other 
hand, VSV takes a more global approach and inhibits host-cell transcription and translation. In both 
cases the IFN antagonism is due to viral proteins that play key roles in virus replication and have 
separate functions involved in inhibition of host antiviral responses, the RABV P protein and the VSV 
M protein.  
5.1. Rabies Virus IFN Escape Mechanisms 
A key viral goal is to control, and minimize, the innate immune response following infection. As 
type I IFN production is critical in an innate response, one mechanism by which a virus can curtail the 
immune response is by diminishing IFN- production. RABV intervenes with the multiple IFN 
induction pathways where most of them converge, namely the activation of IRF-3. The P protein of 
RABV prevents IRF-3 phosphorylation by the TBK1, thus suppressing IFN- production  [115]. It 
seems as though following infection a race between host and virus begins, and thus the expression 
level of RABV P is critical for antagonizing IFN- responses. Brzozka et al. saw that following 
infection with a recombinant RABV that expressed only low levels of P the virus was no longer able to 
suppress IFN- production  [115].  
In addition to antagonizing IFN induction, RABV also has a mechanism to inhibit type I IFN 
signaling. Thus, virus infected cells are resistant to the actions of IFN, regardless from where the 
cytokine originated. Vidy et al. reported that following a RABV infection STAT-1 does not 
accumulate in the nucleus. However, RABV P neither induces STAT-1 degradation nor does it 
interfere with STAT-1 phosphorylation; thus, it was concluded that IFN-induced transcriptional 
responses are prevented   [116]. Recently, Moseley et al. suggested another mechanism by which 
RABV P can interfere with STAT-1 signaling.  It was shown that RABV P can facilitate a shift from 
conventional interaction of STAT-1 and microtubules to a microtubule-inhibited interaction, thus 
preventing STAT-1 nuclear import  [117]. Furthermore, it is known that only tyrosine-phosphorylated 
STAT-1 and -2 are bound by RABV P   [118]. This data indicates that IFN-induced JAK/ STAT 
activation is required for P binding to STAT-1 or -2. It was also determined that binding of RABV P to 
STAT-1 and -2 requires the 10 C-terminal amino acids in RABV P  [118]. 
Of note, RABV P is expressed not only as full-length P protein but also in four N-terminal 
truncated forms (P2-P5) that are synthesized from internal start codons  [119]. While all five P proteins Viruses 2009, 1                                       
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contain a NLS, only two forms, P and P2, have the nuclear export signal (NES) found in the N-
terminus  [119]. Therefore, the P3, P4 and P5 forms are found primarily in the nucleus. Interestingly, P 
not only retains STAT-1 in the cytoplasm but also has the ability to bind the transcription factor in the 
nucleus via P3-P5  [120]. Thus, preventing ISGF3 complexes from binding the ISRE promoter in the 
nucleus  [120].  
Lastly, there is evidence that RABV also interferes directly with IFN-induced antiviral molecules, 
namely PML. The role that PML potentially plays in orchestrating an immune response to RABV or 
impacting viral replication is not yet clear. However, it has been shown in RABV infected cells that 
RABV P retains the PML protein in the cytoplasm and that the P3 isoform disrupts nuclear bodies 
organized in the nucleus   [104]. Thus, disrupting PML’s association with nuclear bodies and 
potentially critical functions in nuclear trafficking, including viral defense and apoptosis  [121]. Again, 
the mechanism by which PML nuclear bodies function in viral infection is still not understood, but the 
binding and retention of PML by RABV P provides some indication that PML may have an antiviral 
function  [104,122].  
5.2. Vesicular Stomatitis Virus IFN Escape Mechanisms 
The matrix protein of VSV is crucial in averting the host IFN- response. VSV M works to 
interrupt cellular transcription pathways and also to block mRNA export from the nucleus, both of 
which function to antagonize the host immune response. The ability of M to inhibit host gene 
expression is genetically separable from its role in virus structure and assembly. Several M protein 
mutant viruses have been identified that are defective in the inhibition of host gene expression, but 
otherwise replicate and assemble as effectively as wildtype VSV  [123-126]. Like RABV P, VSV M 
mRNA is also translated into N-terminally truncated proteins from alternative initiation codons  [127]. 
These truncated proteins also function to inhibit host gene expression, although they are not capable of 
functioning in virus assembly. 
VSV M alone is sufficient to shut down cellular transcription. Expression of VSV M in transfected 
cells inhibits both the host genes and the transfected plasmid transcribed by polymerase I, II, or 
III  [128,129]. M is also capable of inhibiting nuclear-cytoplasmic RNA transport in the absence of 
other VSV components  [130,131]. The general inhibition of host cell transcription leads to significant 
cytotoxicity in VSV infected cells. Of note, transfection of VSV M is sufficient to induce cytopathic 
effects in cells due to the induction of apoptosis  [132,133]. 
Like RABV P, VSV M does not have enzymatic activity, but instead it probably inhibits host 
antiviral responses by binding to host factors and interfering with their normal function. Thus far, the 
only host proteins whose binding to VSV M is correlated with the inhibition of host gene expression 
are Rae1 and the nucleoporin Nup98  [131,134]. These two proteins are present as a complex in cells 
that is thought to be involved in mRNA transport  [135,136], and the binding of M to Nup98 has been 
shown to be indirectly mediated through Rae1  [134]. While binding of M protein to the Rae1-Nup98 
complex is likely to be responsible for the inhibition of nuclear-cytoplasmic RNA transport, this is not 
due simply to the inhibition of Rae1 function, since Rae1 is not essential for mRNA transport. For 
example, silencing Rae1 expression in mammalian cells by siRNA  [137,138] or deletion of Rae1 in 
mouse embryo cells  [139] does not inhibit cellular gene expression. A further question is whether the Viruses 2009, 1                                       
 
 
842
binding of M to Rae1 is also responsible for the inhibition of host transcription, as well as nuclear-
cytoplasmic transport, or alternatively, whether there are additional host factors that are targets for 
VSV M. 
6. Conclusions and Implications for Disease Treatment 
Here we have discussed the different ways by which type I IFN is induced by RABV and VSV, the 
host antiviral proteins that inhibit the viral lifecycle, and the mechanisms by which RABV and VSV 
antagonize IFN- pathways. While both rhabdoviruses can induce IFN-by the RIG-I pathway, it 
seems they use different TLRs. VSV can signal through TLR-7 and TLR-4, while TLR-3 is 
dispensable for inducing IFN. On the other hand, signaling via TLRs is less well studied following a 
RABV infection but there is data to indicate that TLR-3 may play a role. Both RABV and VSV are 
sensitive to Mx GTPases and PML, while only VSV seems to be affected by PKR and ISG15. Lastly, 
these two rhabdoviruses have strikingly different mechanisms to antagonize IFN signaling. RABV 
specifically targets IRF-3 to minimize IFN- production and also inhibits the antiviral response in 
infected cells by binding STAT-1 and -2 and disrupting PML nuclear bodies. On the other hand, VSV 
inhibits cellular transcription pathways and blocks mRNA export to prevent an antiviral response. 
Understanding the host response to VSV and RABV is important for developing vaccines against 
rhabdoviral induced disease but also for developing potential rhabdoviral vaccine vectors. A vaccine 
strain of RABV expressing IFN- greatly reduces viral pathogenesis and replication but not the 
immunogenicity of the vector  [6]. Thus, providing a potentially self-limiting and highly immunogenic 
vaccine vector. Additionally, both RABV and VSV based vaccine vectors have been shown to be 
efficient vaccines against pathogenic SHIV89.6P challenge  [140,141]. Furthermore, VSV has recently 
been considered for potential use as an oncolytic therapy agent. Many transformed cells have impaired 
IFN pathways  [142], thus VSV can replicate to a much greater extent in those cells than normal cells 
that have intact IFN signaling. In fact, it has been reported that transformed cells are more susceptible 
to VSV infection then normal cells following IFN- treatment  [143,144]. Thus, ongoing efforts to 
understand the type I IFN response to rhabdoviruses have obvious implications for improving current 
vaccines and therapies. 
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